Global pharma powerhouse Eli Lilly and Company has unveiled a massive new $4.5 billion expansion across two of its Lebanon, Indiana sites, pushing its total capital investment in the state since 2020 to more than $21 billion.

 

The pharmaceutical company said the latest commitment is driven by its advancing pipeline and rising expected demand for its medicines. 

 

The investment will upgrade and expand production capabilities at Lilly Lebanon API—one of its future active pharmaceutical ingredient hubs—and Lilly Lebanon Advanced Therapies, which opens today as the company’s first dedicated genetic medicine manufacturing facility.

 

Lilly Lebanon Advanced Therapies is built to handle both clinical and commercial production of cutting-edge genetic medicines designed to treat disease at its source. 

 

The facility spans the full spectrum of genetic medicine development, from early research to large-scale manufacturing. It also represents a technical leap forward: Lilly had to design entirely new manufacturing processes without existing commercial models to follow. The site is the first of three planned on the Lebanon campus, alongside Lilly Lebanon API and the future Lilly Medicine Foundry.

 

Lebanon has become the anchor of Lilly’s U.S. manufacturing push. In 2024, the company announced it would produce Zepbound (tirzepatide) and Mounjaro (tirzepatide)—already among the most widely prescribed treatments for weight management and type 2 diabetes—at the site. 

 

The new investment extends that footprint further, adding planned production for Foundayo (orforglipron), described as Lilly’s first FDA-approved once-daily weight-loss pill that requires no food or water restrictions, and retatrutide, an investigational triple hormone receptor agonist in late-stage trials for obesity and cardiometabolic disease.

 

“Lilly's legacy of firsts in Indiana continues today—and the best measure of that legacy is what we do next,” said David A. Ricks, Lilly chair and CEO. 

 

“From genetic medicines that could one day prevent disease at its source, to Foundayo, a pill making weight loss treatment accessible to millions, we are not just discovering the medicines of the future—we are building the world's most advanced plants to make them. When our Lebanon API site opens in 2027, it will be the largest API production site in U.S. history, a commitment we chose to build here, at home.”

 

Indiana leaders also framed the investment as a major economic win for the state.

 

“This expansion reflects the strength of a long-standing partnership between Lilly and the state of Indiana – one that continues to deliver real results for Hoosiers,” said Governor Mike Braun. 

 

“With this investment in Lebanon and across the state, Indiana is reinforcing its position as a prime destination for life sciences and advanced manufacturing, spanning innovation, production and global distribution. Together, we are helping lead the future of medicine while creating high-quality jobs and new opportunities for our communities.”

 

The company’s footprint is also reshaping Indiana’s broader economy. A forthcoming Indiana University Kelley School of Business report highlights Lilly’s outsized role in the state, noting it accounts for 70% of Indiana’s pharmaceutical GDP and that each Lilly job supports more than two additional jobs statewide. 

 

The report also estimates that every dollar spent by the company generates up to four dollars in local economic activity.

 

“Findings from the Kelley School's Indiana Business Research Center report demonstrate Lilly's investments in Indiana are transforming communities across the state in meaningful and far-reaching ways,” said IU President Pamela Whitten. 

 

“Lilly's sustained investments since 2020 underscore the growing strength of Indiana's life sciences sector. Progress at this scale is possible only through robust partnerships, and Indiana University is moving with purpose alongside Lilly to advance innovation that improves health, prepares a world-class workforce and drives economic vitality.”

 

Overall, Lilly says its U.S. capital expansion commitments since 2020 now exceed $50 billion, with multiple new manufacturing sites expected to break ground this year as the company accelerates its domestic production strategy.